Prosecution Insights
Last updated: September 17, 2026
Application No. 18/041,485

COMPOSITIONS AND METHODS OF PRODUCTION THEREOF

Non-Final OA §112
Filed
Feb 13, 2023
Priority
Aug 14, 2020 — GB 2012765.0 +2 more
Examiner
AL-AWADI, DANAH J
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Optibiotix Limited
OA Round
3 (Non-Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
440 granted / 814 resolved
-5.9% vs TC avg
Moderate +14% lift
Without
With
+13.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
26 currently pending
Career history
845
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
47.3%
+7.3% vs TC avg
§102
13.1%
-26.9% vs TC avg
§112
21.2%
-18.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 814 resolved cases

Office Action

§112
DETAILED ACTION RESPONSE TO AMENDMENT 1. The previous action is withdrawn/superseded. Receipt of Applicants’ amendments/remarks filed 8/5/2026 are acknowledged. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 8/5/2026 has been entered. INFORMATION DISCLOSURE STATEMENT 2. Information Disclosure Statement filed 8/5/2026 is acknowledged. WITHDRAWN REJECTIONS 3. Rejections not reiterated from previous Office Actions are hereby withdrawn. The following rejections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 112 4. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-2, 4, 6-9, 11-12, 14, 16, 18-23, 25, 27, 29 and 59 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is missing a period and thus it is not clear what the metes and bounds of the claim is. The dependent claims have been included because they do not cure this deficiency. Claim 19 recites chromium comprises one or more selected from which is treated as comprising. If a Markush grouping requires a material selected from an open list of alternatives (e.g., selected from the group "comprising" or "consisting essentially of" the recited alternatives), the claim is indefinite because it is unclear what other alternatives are intended to be encompassed by the claim. See In re Kiely, 2022 USPQ2d 532 at 2* (Fed. Cir. 2022). It is suggested to amend the claim to recite wherein the chromium is one or more selected from the group consisting of. CORRESPONDENCE 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danah Al-awadi whose telephone number is (571) 270-7668. The examiner can normally be reached on 9:00 am - 6:00 pm; M-F (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANAH AL-AWADI/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Show 1 earlier event
May 21, 2025
Non-Final Rejection mailed — §112
Aug 21, 2025
Response Filed
Nov 19, 2025
Final Rejection mailed — §112
Mar 19, 2026
Request for Continued Examination
Mar 20, 2026
Response after Non-Final Action
Aug 05, 2026
Request for Continued Examination
Aug 27, 2026
Response after Non-Final Action
Aug 31, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734124
EYELASH COATING COMPOSITIONS FOR FALSE EYELASHES
2y 9m to grant Granted Sep 15, 2026
Patent 12728134
LIQUISOLID PHARMACEUTICAL FORMULATION AND PROCESS FOR MANUFACTURING
3y 10m to grant Granted Sep 08, 2026
Patent 12721804
EMULSIFIED LIP GEL
4y 2m to grant Granted Sep 01, 2026
Patent 12721831
TETRAHYDROCURCUMINOID-METAL COMPLEXES, MANUFACTURING METHODS THEREOF, AND USES THEREOF
2y 4m to grant Granted Sep 01, 2026
Patent 12714725
STABILIZATION OF SELENITE IN A NUTRITIONAL SOLUTION BY DISSOLVED OXYGEN
4y 2m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
68%
With Interview (+13.6%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 814 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month